Stockholm, Sweden, June 10, 2026. Egetis Therapeutics AB (publ) (“Egetis” or the “Company”) (Nasdaq Stockholm: EGTX), an innovative pharmaceutical company focused on late-stage development and commercialization of treatments for serious rare diseases with significant unmet medical needs, today announced the re-airing of a special episode of Behind the Mystery™, a television series featured on The […]
Stockholm, 24 februari 2022 – Egetis Therapeutics AB (publ) (Nasdaq Stockholm: EGTX) lanserar idag #MCT8Hugs – ett globalt online-initiativ för att öka medvetenheten om MCT8-brist. MCT8-brist är en sällsynt och livsförkortande genetisk sjukdom som orsakar kritiska konsekvenser som allvarligt nedsatt neurokognitiv utveckling och motorisk funktion. Hos de flesta av de drabbade resulterar detta i en […]
Stockholm, Sweden, February 24, 2022 – Egetis Therapeutics AB (publ) (Nasdaq Stockholm: EGTX) today launched #MCT8Hugs – a global, online initiative to drive awareness of MCT8 deficiency. MCT8 deficiency is a rare and life-shortening genetic disease, causing serious consequences such as severely impaired neurocognitive development and motor function. In most of those affected, this results […]